CIPN
What is CIPN
.png)
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent complication of cancer chemotherapy treatment, causing sensory disturbances, balance problems, and/or weakness due to injury of peripheral nerves. CIPN affects a significant number of cancer patients, with an estimated 68% prevalence in the first month after chemotherapy, 60% at three months, and 30% at six months following their last dose of chemotherapy.
Novel Treatment
SP16, stimulates the body’s innate mechanisms for inflammation management. When SP16 binds to the homeostatic receptor low density lipoprotein receptor related protein-1 (LRP1), harmful molecules and pathogens are cleared from the cell surface, and pathways associated with inflammation and cell death become less active. As a result of this LRP1 agonism activity, treatment with SP16 has the potential to reduce the progression of inflammation.
In preclinical models, SP16 was shown to:
-
Alleviate neuropathic pain
-
Reduce inflammation at the site of nerve injury
-
Improve nerve survival, growth, and regenerative signaling
About SP16
.png)
-
SP16 is a 17 amino acid peptide containing the active portion of A1AT activating LRP1
-
SP16 administered via IV formulation with two hypothesized actions:
-
Anti-inflammatory (analgesic) action via reduction of IL-6, IL-8, IL-1β and TNF-alpha
-
Potential to repair tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation, and survival
CINP
CINP Chemotherapy treatments can cause peripheral neuropathy by damaging the nerves in the extremities.
Diseases
CIPN
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent complication of cancer chemotherapy treatment.
